Abemaciclib API is a highly selective cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) inhibitor. CDK4 and CDK6 are two key enzymes that play a critical role in cell cycle regulation. Abemaciclib API works by inhibiting CDK4 and CDK6, which halts the cell cycle progression and leads to apoptosis (programmed cell death) of cancer cells.

Abemaciclib API is used in the treatment of advanced or metastatic breast cancer (ABC/MBC) and hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic non-small cell lung cancer (NSCLC). It is also being investigated for the treatment of other types of cancer, such as colorectal cancer, pancreatic cancer, and ovarian cancer.

Abemaciclib API is typically administered orally once daily in combination with other chemotherapy drugs. It is generally well-tolerated, but common side effects can include diarrhea, nausea, fatigue, and neutropenia (low white blood cell count).

Qingmu Pharm is a leading manufacturer and supplier of abemaciclib API. The company produces high-quality abemaciclib API that is used to manufacture abemaciclib-based medicines around the world.

Here are some of the key details about Qingmu Pharm's abemaciclib API:

• Product name:Abemaciclib API
• CAS number:1298869-65-6
• Molecular formula:C27H31N7O
• Molecular weight:63 g/mol
• Appearance:White to light yellow crystalline powder
• Solubility:Soluble in DMSO, methanol, and ethanol
• Purity:≥99%

Qingmu Pharm's abemaciclib API is manufactured in accordance with the highest quality standards and is compliant with cGMP and ISO standards. The company's abemaciclib API is registered with regulatory authorities in over 50 countries around the world.